Cargando…
Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.
Fifty-seven patients with advanced prostate cancer resistant to first-line hormonal therapy were treated with estramustine and additionally randomized for treatment with clodronate or placebo. Clodronate treatment was started with 5 days intravenous administration (300 mg day[-1]) and followed by or...
Autores principales: | Kylmälä, T., Taube, T., Tammela, T. L., Risteli, L., Risteli, J., Elomaa, I. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228066/ https://www.ncbi.nlm.nih.gov/pubmed/9328156 |
Ejemplares similares
-
Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
por: Kylmälä, T., et al.
Publicado: (1995) -
Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.
por: Elomaa, I., et al.
Publicado: (1992) -
Type III collagen metabolism in soft tissue sarcomas.
por: Wiklund, T. A., et al.
Publicado: (1992) -
Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients.
por: Saarto, T., et al.
Publicado: (1998) -
Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.
por: Blomqvist, C., et al.
Publicado: (1996)